SEI Investments’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

SEI Investments’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,329	Closed	-$378K	–	2790
2023 Q1	$378K	Sell	16,329 -2,628	-14%	-$62.6K	﹤0.01%	2244
2022 Q4	$497K	Sell	18,957 -3,712	-16%	-$82.2K	﹤0.01%	2003
2022 Q3	$446K	Sell	22,669 -710	-3%	-$14.2K	﹤0.01%	2140
2022 Q2	$409K	Buy	+23,379	New	+$367K	﹤0.01%	2185
2016 Q3	–	Sell	-119	Closed	-$7K	–	3022
2016 Q2	$7K	Buy	119 +12	+11%	+$729	﹤0.01%	2343
2016 Q1	$7K	Sell	107 -7	-6%	-$566	﹤0.01%	2251
2015 Q4	$16K	Sell	114 -246	-68%	-$33.4K	﹤0.01%	2159
2015 Q3	$35K	Sell	360 -796	-69%	-$94.8K	﹤0.01%	1981
2015 Q2	$175K	Buy	+1,156	New	+$191K	﹤0.01%	1416

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SEI Investments's KDNY Position: Q2 2023 in Review

SEI Investments sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 16,329 shares — an estimated $378K sold.

SEI Investments first reported a position in KDNY in Q2 2015 and held it in 9 quarters. The position peaked at $497K in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

SEI Investments reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
SEI Investments sold 16,329 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $378K.
SEI Investments first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 9 quarters.
SEI Investments's Chinook Therapeutics, Inc. Common Stock position peaked at $497K in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on SEI Investments's 13F filing for Q2 2023, filed 11 Aug 2023.